Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Industry: Healthcare

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Current Quote*
Last: $53.070
Change: -1.930
Book: $5.649
Volume: 1,800,424

As Of: 06/14 13:24 ET
*Quotes delayed by 20min.

Graphs for GBT


3 Month Graph


6 Month Graph


1 Year Graph